Multifocal Glioblastoma Multiforme Preceded by a Gemistocytic Astrocytoma and Dysregulated Immune Response

Koev, Ilian G.; Slavov, E.; Zhelyazkov, Hristo; Staikov, D. G.; Halacheva, Krasimira; Sarafian, Victoria

doi:10.5272/jimab.2014202.502

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it can also not be ruled out that the glioblastoma micro-environment plays a role in inducing systemic inflammation facilitating sarcopenia. Although glioblastoma is historically not considered a ‘systemic’ disease, evidence of glioblastoma-derived mechanisms of, for example, systemic immunosuppression is emerging in the past decade [ 30 ]. Interestingly, skeletal muscle is postulated as potential central link between sarcopenia and immune senescence in elderly [ 31 ], which further supports the role of skeletal muscle loss in immune regulatory processes.…”

Section: Discussionmentioning

confidence: 99%

Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients

et al. 2022

View full text Add to dashboard Cite

Purpose Reduced temporal muscle thickness (TMT) has recently been postulated as a prognostic imaging marker and an objective tool to assess patients frailty in glioblastoma. Our aim is to investigate the correlation of TMT and systemic muscle loss to confirm that TMT is an adequate surrogate marker of sarcopenia in newly diagnosed glioblastoma patients. Methods TMT was assessed on preoperative MR-images and skeletal muscle area (SMA) was assessed at the third lumbar vertebra on preoperative abdominal CT-scans. Previous published TMT sex-specific cut-off values were used to classify patients as ‘patient at risk of sarcopenia’ or ‘patient with normal muscle status’. Correlation between TMT and SMA was assessed using Spearman’s rank correlation coefficient. Results Sixteen percent of the 245 included patients were identified as at risk of sarcopenia. The mean SMA of glioblastoma patients at risk of sarcopenia (124.3 cm2, SD 30.8 cm2) was significantly lower than the mean SMA of patients with normal muscle status (146.3 cm2, SD 31.1 cm2, P < .001). We found a moderate association between TMT and SMA in the patients with normal muscle status (Spearman’s rho 0.521, P < .001), and a strong association in the patients at risk of sarcopenia (Spearman’s rho 0.678, P < .001). Conclusion Our results confirm the use of TMT as a surrogate marker of total body skeletal muscle mass in glioblastoma, especially in frail patients at risk of sarcopenia. TMT can be used to identify patients with muscle loss early in the disease process, which enables the implementation of adequate intervention strategies.

show abstract

Section: Discussionmentioning

confidence: 99%